Share this post on:

Leflunomide

Leflunomide inhibits dihydroorotate dehydrogenase, preventing UMP formation and pyrimidine synthesis. Metabolites of leflunomide may inhibit various kinases such as JNK and JAK. Leflunomide is clinically used to treat rheumatoid arthritis; it exhibits immunosuppressive, antiviral, and anticancer activities. In several cellular models, leflunomide prevents apoptosis and increases viability in human cytomegalovirus (CMV)-infected cells and inhibits replication of polyomavirus BK. Additionally, leflunomide increases activity of aryl hydrocarbon receptors, inhibiting proliferation of melanoma cells.

References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/18938072

Cas No.

75706-12-6

Purity

≥98%

Formula

C12H9F3N2O2

Formula Wt.

270.21

Chemical Name

5-Methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide

IUPAC Name

5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide

Synonym

HWA-486; Arava

Melting Point

166.5°C

Solubility

Soluble in DMSO or methanol.

Appearance

White or off-white crystalline powder

Qi R, Hua-Song Z, Xiao-Feng Z. Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. Eur J Med Res. 2013 Feb 1;18:3. PMID: 23369524.

ODonnell EF, Kopparapu PR, Koch DC, et al. The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells. PLoS One. 2012;7(7):e40926. PMID: 22815870.

Bernhoff E, Tylden GD, Kjerpeseth LJ, et al. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol. 2010 Feb;84(4):2150-6. PMID: 19955306.

Pinto P, Dougados M. Leflunomide in clinical practice. Acta Reumatol Port. 2006 Jul-Sep;31(3):215-24. PMID: 17094333.

INK-129